K080107 · bioMerieux, Inc. · LON · Feb 28, 2008 · Microbiology
Device Facts
Record ID
K080107
Device Name
VITEK 2 GRAM NEGATIVE PIPERACILLIN/TAZOBACTAM
Applicant
bioMerieux, Inc.
Product Code
LON · Microbiology
Decision Date
Feb 28, 2008
Decision
SESE
Submission Type
Traditional
Regulation
21 CFR 866.1645
Device Class
Class 2
Attributes
Real-World Evidence
Real-World Evidence
Submission
Device
Sponsor
RWD Sources
RWE Use Summary
Key Tags
K080107 · Feb 28, 2008
VITEK 2 GRAM NEGATIVE PIPERACILLIN/TAZOBACTAM
bioMerieux, Inc.
Clinical isolates (fresh and stock)
Clinical isolates were used to evaluate the performance of the VITEK 2 Gram Negative Piperacillin/Tazobactam AST card by comparing results to the CLSI broth microdilution reference method.
Essential Agreement, Category Agreement, and reproducibility
Indications for Use
VITEK® 2 Gram Negative Piperacillin/tazobactam is designed for antimicrobial susceptibility testing of gram-negative organisms and is intended for use with the VITEK® 2 Compact Systems as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. VITEK 2 Gram Negative Piperacillin/tazobactam is a quantitative test. Piperacillin/ tazobactam has been shown to be active against most strains of the organisms listed below according to the FDA label for the antimicrobial. Active in vitro and in clinical infections Klebsiella pneumoniae Acinetobacter baumanii Escherichia coli Pseudomonas aeruginosa Active in vitro but their clinical significance is uknown: Proteus vulgaris Providencia rettgeri Providencia stuartii Citrobacter koseri Morqanella morganii Proteus mirabilis Salmonella enterica Serratia marcescens The VITEK® 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the VITEK® 2 and VITEK® 2 Compact Systems for the automated quantitative or qualitative susceptibility testing of isolated colonies for the most clinically significant aerobic gram-negative bacilli, Staphylococcus spp., Enterococcus spp., Streptococcus agalactiae, and S. pneumoniae.
Device Story
VITEK® 2 AST system performs automated antimicrobial susceptibility testing. Input: standardized organism suspension (McFarland 0.5) inoculated into 64-microwell test cards. Operation: instrument vacuum-fills cards; seals; incubates at 35.5°C; performs optical scanning every 15 minutes. Algorithm: quantitative growth-based detection using optical light monitoring; determines susceptibility based on predetermined growth thresholds. Output: automated quantitative or qualitative susceptibility report. Used in clinical laboratories by technicians/lab staff. Benefits: rapid, standardized determination of bacterial susceptibility to Piperacillin/tazobactam, aiding clinical antibiotic selection.
Clinical Evidence
Bench testing only. Performance evaluated using 483 clinical isolates (269 fresh, 214 stock) and 79 challenge isolates. Comparison against broth microdilution reference method. Combined results showed 96.6% Essential Agreement and 96.6% Category Agreement. Reproducibility >95% across 3 sites. Quality control testing performed with E. coli and P. aeruginosa strains, meeting expected ranges >95% of the time.
Technological Characteristics
VITEK® 2 AST card with 64 microwells containing premeasured antibiotic and culture medium. Optical sensing principle; 35.5°C incubation. Automated vacuum filling and sealing. Connectivity: VITEK® 2 and VITEK® 2 Compact Systems. Software-based growth detection algorithm.
Indications for Use
Indicated for in vitro susceptibility testing of Acinetobacter baumanii, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Citrobacter koseri, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Providencia rettgeri, Salmonella enterica, and Serratia marcescens to Piperacillin/tazobactam (concentrations 4/4, 16/4, 32/4, 64/4; calling range ≤4 - ≥128 μg/mL) in clinical laboratories.
Regulatory Classification
Identification
A fully automated short-term incubation cycle antimicrobial susceptibility system is a device that incorporates concentrations of antimicrobial agents into a system for the purpose of determining in vitro susceptibility of bacterial pathogens isolated from clinical specimens. Test results obtained from short-term (less than 16 hours) incubation are used to determine the antimicrobial agent of choice to treat bacterial diseases.
Special Controls
*Classification.* Class II (special controls). The special control for this device is FDA's guidance document entitled “Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA.”
{0}
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY ONLY TEMPLATE
A. 510(k) Number:
K080107
B. Purpose for Submission:
The addition of Piperacillin/tazobactam to the VITEK® 2 and VITEK®2
Compact Systems Antimicrobial Susceptibility Test (AST) System.
C. Measurand
VITEK® 2 Gram Negative Piperacillin/tazobactam (≤ 4- ≥ 128 μg/ml)
D. Type of Test:
Quantitative growth based detection algorithm using optics light detection
E. Applicant:
bioMerieux, Inc.
F. Proprietary and Established Names:
Vitek®2 Gram Negative Piperacillin/tazobactam
G. Regulatory Information:
1. Regulation section:
866.1645 Short-Term Antimicrobial Susceptibility Test System
2. Classification:
II
3. Product Code:
LON System, Test, Automated, Antimicrobial Susceptibility, Short Incubation
4. Panel:
83 Microbiology
H. Intended Use:
1. Intended use(s):
Piperacillin/tazobactam at concentrations of ≤ 4- ≥ 128 μg/mL on the Gram
Negative Susceptibility Card is intended for use with the VITEK®2 Systems
for the automated quantitative or qualitative susceptibility testing of isolated
colonies for most clinically significant aerobic Gram-negative bacilli,
Staphylococcus spp., Enterococcus spp., Streptococcus agalactiae, S.
pneumoniae, and yeast.
2. Indication(s) for use:
{1}
Page 2 of 12
This submission is indicated for the addition of Piperacillin/tazobactam at concentrations of 4/4, 16/4, 32/4, 64/4 for a calling range of ≤4 - ≥128 μg/mL on the VITEK®2 Gram Negative Susceptibility Cards for use with the VITEK®2 Systems in clinical laboratories as an in vitro test to determine the susceptibility of Acinetobacter baumanii, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Citrobacter koseri, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Providencia rettgeri, Salmonella enterica, and Serratia marcescens to antimicrobial agents when used as instructed in the Online Product Information.
3. Special condition for use statement(s):
Prescription Use Only
4. Special instrument Requirements:
Not Applicable
I. Device Description:
The VITEK® 2 AST card containing the test is inoculated with a standardized organism suspension. The card is incubated within the instrument and optically monitored throughout the incubation cycle. Results are automatically calculated once a predetermined growth threshold is reached and a report is generated that contains the final result.
J. Substantial Equivalence Information:
1. Predicate device name(s):
VITEK® 2 Gram Negative Levofloxacin
2. Predicate K number(s):
K072038
3. Comparison with predicate
| Similarities | | |
| --- | --- | --- |
| Item | Device | Predicate |
| Test organism | Gram Negative Rods Colonies | same |
| Test Card | VITEK® 2 card format with base broth | same |
| Instrument | VITEK® 2 and VITEK®2 Compact System | same |
| Differences | | |
| Item | Device | Predicate |
| Antibiotic | Piperacillin/tazobactam | Levofloxacin |
| Reading algorithm | Unique for new formulation of Piperacillin/tazobactam | Unique for Levofloxacin |
{2}
Page 3 of 12
## K. Standard/Guidance Document Referenced (if applicable):
Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA”; CLSI M7 (M100-S18) “Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard”
## L. Test Principle:
Each VITEK®2 test card contains 64 microwells. A control well, that contains only microbiological culture medium is resident on all cards, with the remaining wells containing premeasured amounts of a specific antibiotic combined with culture medium. A suspension of organism is made in 0.45-0.5% sterile saline from a pure culture and standardized to a McFarland 0.5 standard using the DensiChek. The desired cards are placed in the cassette along with an empty tube for the susceptibility card. The cassette is placed in the VITEK®2 instrument where a susceptibility test will be automatically diluted from the ID suspension by the VITEK®2. The cards are then automatically vacuum filled; the tubes are cut and the cards sealed prior to proceeding to the Incubator Loading Station. Cards are then transferred from the cassette into the carousel for incubation (35.5° C) and optical scanning during testing. Readings are performed every 15 minutes. In addition to the automatic dilution, there is also a manual inoculation dilution procedure described in the packager insert.
## M. Performance Characteristics (if/when applicable):
Two AST (TZP1 and TZP2) will be identified in the product labeling (package inserts and the VITEK®2 System Product Information, Susceptibility Performance Characteristics). TZP1 will identify information related to the original test (N50510/S119) and TZP2 will identify information related to this submission.
## This submission is for the AST Panel only. The ID System was not reviewed.
### 1. Analytical performance:
a. Precision/Reproducibility:
Reproducibility was demonstrated using 10 isolates at 3 sites on 3 separate days in triplicates. The study included the Auto-dilution and the Manual dilution. All results were >95% reproducible and acceptable.
b. Linearity/assay reportable range:
Not Applicable
c. Traceability (controls, calibrators, or method):
Three recommended QC (E. coli ATCC 25922, E. coli ATCC 35218 and P. aeruginosa ATCC 27853) were tested a minimum 20 times/site by the automatic dilution and the manual dilution. The organisms were tested by the VITEK 2 AST cards and the reference (broth microdilution) methods.
{3}
The following table provides the frequency of results for all sites in each concentration with the expected range stated. Both the Auto dilution and the Manual dilution methods are within the expected range $>95\%$ of the time. The Reference Results are similar to the test results. In instances where any organism was out of range for the reference method, all testing data was invalid and repeated.
| Organism | Conc in μg/ml | Auto-dilution | | Manual dilution | |
| --- | --- | --- | --- | --- | --- |
| E. coliATCC 25922Range1-4 μg/ml | | Ref. | Test | Ref. | Test |
| | ≤4 | 108 | 108 | 85 | 85 |
| | 8 | | | | |
| | 16 | | | | |
| | 32 | | | | |
| | 64 | | | | |
| | 128 | | | | |
| | ≥256 | | | | |
| E. coliATCC 35218Range0.5-2 μg/ml | ≤4 | 105 | 104 | 83 | 82 |
| | 8 | | | | |
| | 16 | | | | |
| | 32 | | | | |
| | 64 | 1 | | 1 | |
| | 128 | 1 | 4 | 1 | 2 |
| | ≥256 | 1 | | 1 | |
| | | | | | |
| P. aeruginosaATCC 27853Range1-8 μg/ml | ≤4 | 84 | 104 | 72 | 84 |
| | 8 | 18 | | 13 | |
| | 16 | 2 | | 1 | |
| | 32 | | | | |
| | 64 | | | | |
| | 128 | | | | 1 |
| | ≥256 | | | | |
Inoculum density control:
A turbidity meter (VITEK 2 DensiChek) was used to adjust the inoculum to the turbidity of $0.5\mathrm{McFarland}$ . The VITEK 2 DensiChek instrument was standardized weekly with all results recorded and in the expected range. Verification was performed during internal testing.
d. Detection limit: Not Applicable
e. Analytical specificity: Not Applicable
f. Assay cut-off: Not Applicable
2. Comparison studies:
{4}
Page 5 of 12
a. Method comparison with predicate device:
Clinical study was performed at three external sites using the VITEK 2 AST-GN Piperacillin/tazobactam and broth microdilution panels containing Piperacillin/tazobactam. The study included 483 clinical isolates (269 fresh, 214 stock) and a challenge set of 79 isolates. The clinical stock isolates were <50%. Two methods of inoculation (manual and automated) were evaluated. Clinical testing was performed by the automated method of inoculation and the challenge set was by both the manual and the automated methods. All isolates grew in the VITEK®2 cards in less than 16 hours. The test device had a growth rate of >95% for the clinical and the challenge study.
The vmj was 2.3% (4/176). Pseudomonas aeruginosa, Acinetobacter baumannii, E. coli and K. pneumoniae each had one vmj. There is no intermediate category in the interpretative criteria for P. aeruginosa so all discrepant results are either very major error (vmj) or a major error (maj), even the result is within EA. The vmj was within EA. The vmj for Acinetobacter baumannii and K. pneumoniae were 1.3% (1/76) and 1.4% (1/71) respectively. They all had an acceptable EA and CA of >90%.
Summary Table for Acinetobacter baumannii, Enterobacteriaceae and Pseudomonas aeruginosa (Auto Dilution)
| | total | EA | %EA | Eval EA Total | Eval EA | Eval %EA | CA | %CA | #R | min | maj | vmj |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Clinical | 483 | 469 | 97.1 | 68 | 67 | 98.5 | 470 | 97.3 | 169 | 7 | 2 | 4 |
| Challenge | 79 | 74 | 93.7 | 19 | 17 | 89.5 | 73 | 92.4 | 7 | 3 | 3 | 0 |
| Combined | 562 | 543 | 96.6 | 87 | 84 | 96.6 | 543 | 96.6 | 176 | 10 | 5 | 4 |
EA-Essential Agreement
CA-Category Agreement
R-resistant isolates
maj-major discrepancies
vmj-very major discrepancies
min- minor discrepancies
Manual Dilution:
The challenge set of 109 organisms was also tested at one site using the manual method of inoculation with the following performance. There was no difference in the overall CA agreement.
Comparison Challenge Data - Auto vs Manual dilution
| | total | EA | %EA | Eval EA Total | Eval EA | Eval %EA | CA | %CA | #R | min | maj | vmj |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Auto | 109 | 103 | 94.5 | 24 | 22 | 91.7 | 98 | 90 | 14 | 7 | 3 | 1 |
| Manual | 109 | 101 | 92.7 | 22 | 19 | 86.4 | 97 | 90 | 14 | 7 | 3 | 1 |
b. Matrix comparison:
Not Applicable
3. Clinical studies:
{5}
Page 6 of 12
a. Clinical sensitivity: Not Applicable
b. Clinical specificity: Not Applicable
c. Other clinical supportive data (when a and b are not applicable):
4. Clinical cut-off: Not Applicable
5. Expected values/Reference range
The interpretative criteria and the recommended Quality Control ranges are the same as the FDA and CLSI and will appear in the Package Insert and software. Interpretative criteria used for the evaluation and that will appear in the Package Insert are as follows:
Enterobacteriaceae and Acinetobacter baumanii
≤ 16 (S) 32-64(I) ≥ 128 (R)
Pseudomonas aeruginosa
≤ 64 (S) --- ≥ 128 (R)
N. Proposed Labeling:
The expected value range, interpretive criteria and QC are included in the package insert. The labeling is sufficient and it satisfies the requirement of 21 CFR Part 809.10.
O. Conclusion:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision
{6}
Page 7 of 12
